NASDAQ
Coeptis Therapeutics, Inc. (COEP) has a free cash flow growth of -4.21% as of Friday, May 29, 2026. This represents a 50.86% increase compared to its 12-month average of -8.56%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.